Figure 3.
Ptsn enables integrin activation in a human T cell line. (A) Relative expression of Ptsn and RIAM in human tissues. Adapted from the Human Proteome Map portal (https://www.humanproteomemap.org). (B) KO of Ptsn in Jurkat T cells reduces integrin activation. PPP1R18 gene encoding Ptsn was knocked out in Jurkat T cells using CRISPR/Cas9, and soluble VCAM-1 binding was assessed by flow cytometry. Cellular stimulation was performed using PMA (100 nM). The activation index was calculated as (F − Fo)/(Fm − Fo), where F is the MFI of VCAM-1 binding, Fo is the MFI in presence of EDTA, and Fm is the MFI upon addition of MnCl2. Bar graphs represent mean ± SEM (n = 3 independent experiments). Two-way ANOVA with Tukey post-test; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) The expression of Ptsn was confirmed by immunoblotting. Results are representative of three independent experiments. Source data are available for this figure: SourceData F3.

Ptsn enables integrin activation in a human T cell line. (A) Relative expression of Ptsn and RIAM in human tissues. Adapted from the Human Proteome Map portal (https://www.humanproteomemap.org). (B) KO of Ptsn in Jurkat T cells reduces integrin activation. PPP1R18 gene encoding Ptsn was knocked out in Jurkat T cells using CRISPR/Cas9, and soluble VCAM-1 binding was assessed by flow cytometry. Cellular stimulation was performed using PMA (100 nM). The activation index was calculated as (F − Fo)/(Fm − Fo), where F is the MFI of VCAM-1 binding, Fo is the MFI in presence of EDTA, and Fm is the MFI upon addition of MnCl2. Bar graphs represent mean ± SEM (n = 3 independent experiments). Two-way ANOVA with Tukey post-test; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (C) The expression of Ptsn was confirmed by immunoblotting. Results are representative of three independent experiments. Source data are available for this figure: SourceData F3.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal